Imagion Biosystems Ltd. (IBX) AI Stock Analysis

Imagion Biosystems has signed a Master Service Agreement with nanoComposix, a specialty nanoparticle CDMO, to resume pharmaceutical-grade manufacturing of its MagSense® nanoparticles in alignment with U.S. FDA product quality standards. By outsourcin...

Imagion Biosystems has released an investor presentation outlining its molecular MRI platform as a next-generation imaging technology for early cancer detection. The company positions this approach as a breakthrough in oncology imaging, aiming to enh...

Imagion Biosystems has issued a cleansing notice following the allotment of 40,208,334 listed options expiring on 13 December 2027, including options granted to participants in a recent placement and to the lead manager. The options were issued witho...

Imagion Biosystems Limited has applied to the ASX for quotation of new options, designated under the security code IBXO, further integrating these instruments into its listed securities structure. The options relate to securities issued to the lead m...

Imagion Biosystems has applied to the ASX for quotation of new options under the code IBXO, expanding its listed securities on the market. The company is seeking quotation for a total of 32,708,334 options expiring on 13 December 2027, issued across...

Imagion Biosystems has announced the expiry and cessation of 1,164,597 listed options with the ASX code IBXAAU, which carried an exercise price of $0.90 and an expiry date of August 25, 2026. The options lapsed without being exercised, resulting in a...

Imagion Biosystems has disclosed a change in Director Robert Romeo Proulx’s interests in the company’s securities, detailing his holdings of ordinary shares, listed and unlisted options, and multiple classes of performance rights tied to clinical and...

Imagion Biosystems reported a half-year loss after tax of $1.98 million for the period ended 30 June 2026, a 19.2% increase on the prior corresponding period, with no dividends declared or paid. Net tangible assets per share fell to negative 0.63 cen...

Imagion Biosystems has issued 152,549,425 fully paid ordinary shares at $0.012 per share and 156,250,023 listed options expiring in December 2027 as part of a previously announced placement. The company lodged a cleansing notice under Section 708A of...

Imagion Biosystems has applied for quotation on the ASX of over 152.5 million new ordinary fully paid shares and an equal volume of options expiring in December 2027. The newly issued securities, tied to a previously announced transaction, expand the...

Imagion Biosystems has issued 108,521,193 fully paid ordinary shares as part of Tranche 2 of a previously announced placement, and has lodged a cleansing notice under Section 708A of the Corporations Act. The company confirms it has met its continuou...

Imagion Biosystems Limited has applied for the quotation of 108,521,193 ordinary fully paid shares on the ASX, with the securities issued on August 17, 2026. The application, lodged as a new announcement, confirms the company’s intention to have thes...

Imagion Biosystems Limited has reported the results of a general meeting at which shareholders voted on a series of capital-related resolutions by poll. The meeting confirmed strong support for the company’s financing activities, with each resolution...

Imagion Biosystems Ltd. has notified the ASX of a proposed issue of up to 17,875,000 ordinary fully paid shares as part of a placement or similar capital-raising structure. The new securities are expected to be issued on 30 November 2026, with the co...

Imagion Biosystems has secured a non-dilutive short-term funding facility through an unsecured loan agreement with its executive chairman, Robert Proulx, providing up to US$150,000 in working capital. The loan carries an 8% annual interest rate on dr...

Imagion Biosystems Limited has called a virtual General Meeting for shareholders to be held on 10 August 2026 at 10:00am AEST via a webinar conferencing facility, with voting eligibility set for registered shareholders as at 8 August 2026. The compan...

Imagion Biosystems has renewed and extended its collaboration agreement with Siemens Healthineers to support its recently cleared Phase 1b/2 clinical trial of the MagSense HER2 breast cancer imaging agent. Siemens will provide in-kind MRI expertise a...

Imagion Biosystems has issued 49,346,051 new fully paid ordinary shares at $0.012 per share as part of Tranche 1 of a previously announced placement, and has lodged a cleansing notice under Section 708A of the Corporations Act. The company confirms i...

Imagion Biosystems has applied for quotation on the ASX of 49,346,051 new fully paid ordinary shares, with an issue date of 30 June 2026. The additional securities, issued under a previously announced transaction, will expand the company’s quoted sha...